Ready to start the #MaTOS24 conference at Lake Tahoe with Drs. Luis Raez and Marina Garassino!

#MaTOS24 closes - was great to learn with and from close friends in Lake Tahoe!

Really engaging discussion on #SCLC at #MaTOS24 with Drs. Paul Bunn, Noura Choudhury, Ticiana Leal, Christine Hann, Puneeth Iyengar, Misty Shields. #LCSM #OncSky

It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.

What is the future of #EGFR exon 20 NSCLC? Dr. Zosia Piotrowska at #MaTOS24 outlines some ongoing front line studies. Which will emerge as the best practice? #LCSM #OncSky

#MaTOS24 was full of high level discussion about treatment of lung cancer. Spirited debate and discussion among close friends and colleagues - always something special!

Dr. Liza Villaruz at #MaTOS24 discusses #NTRK and NSCLC. Three approved agents: larotrectinib, entrectinib, and now repotrectinib. Effective but note on target toxicities including dizziness, paresthesias, weight gain, pain withdrawal - on target toxicities to watch for. #LCSM #OncSky

Flew from Shanghai to Seattle to Lake Tahoe yday to attend #MaTOS24 conference today, where Claudia Henschke kicks off on screening.

Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.

Dr. Puneeth Iyengar reviews radiation in #SCLC at #MaTOS24. Role of PCI needs to be clarified and ongoing studies will provide clarity. Concurrent IO and definitive thoracic radiation seems like the wrong strategy. It’s a radiosensitive disease - how do we leverage that?

Dr. Ticiana Leal at #MaTOS24 discusses biomarkers in #SCLC. How do we use differential expression of transcriptional regulators? How do we assess the immunosuppressive microenvironment? Can we target MHC-I deficiency? #LCSM #OncSky

Dr. Jay Lee at #MaTOS24 discusses perioperative therapy. Impressive DFS benefit from adding immunotherapy to neoadjuvant chemo in NSCLC but for now, only OS benefit is pembrolizumab in KEYNOTE 671. Attrition before surgery is a concern - somewhat high rates - due to selection?

Looking ahead for #SCLC with Dr. Misty Shields at #MaTOS24. Where will ADCs and BiTEs make the biggest impact? What are the optimal targets and payloads? How will maintenance lurbinectedin change outcomes? What role will radiation play? #LCSM #OncSky

Current treatment for #SCLC discussed by Dr. Christine Hann at #MaTOS24. Current 1L standard is chemo + immunotherapy (atezolizumab or durvalumab). 2L options are lurbinectidin or tarlatamab. IMforte press release shows maintenance lurbi improves OS and PFS. Stay tuned. #LCSM #OncSky